Twist Bioscience Stock Holdings Lifted by Rafferty Asset Management

Institutional investor increases stake in synthetic biology company by over 50%

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC, an institutional investor, has increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 51% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. Rafferty now owns 114,268 shares of the company's stock, worth approximately $3.2 million.

Why it matters

Twist Bioscience is a prominent player in the synthetic biology industry, known for its proprietary DNA synthesis platform. This increase in institutional ownership signals growing investor confidence in the company's technology and future prospects.

The details

According to the 13F filing, Rafferty Asset Management acquired an additional 38,608 shares of Twist Bioscience in the third quarter, bringing its total ownership to 114,268 shares, or 0.19% of the company's outstanding stock. The move comes as Twist Bioscience has seen its share price fluctuate in recent months, with the stock trading between $23.30 and $57.88 over the past 52 weeks.

  • Rafferty Asset Management increased its stake in Twist Bioscience in the 3rd quarter of 2025.

The players

Rafferty Asset Management LLC

An institutional investor that manages a portfolio of stocks, including a position in Twist Bioscience Corporation.

Twist Bioscience Corporation

A synthetic biology company that specializes in the development and commercialization of DNA-based products and solutions, using a proprietary silicon-based DNA synthesis platform.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Rafferty Asset Management in Twist Bioscience suggests that institutional investors see long-term potential in the company's innovative DNA synthesis technology and its ability to capitalize on growth opportunities in the synthetic biology market.